Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00190892
Registration number
NCT00190892
Ethics application status
Date submitted
12/09/2005
Date registered
19/09/2005
Date last updated
26/01/2007
Titles & IDs
Public title
Olanzapine Plus Carbamazepine in the Treatment of Bipolar I Mania
Query!
Scientific title
Olanzapine Plus Carbamazepine Versus Carbamazepine Alone in the Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder
Query!
Secondary ID [1]
0
0
F1D-MC-HGKR
Query!
Secondary ID [2]
0
0
7031
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Bipolar Disorder
0
0
Query!
Condition category
Condition code
Mental Health
0
0
0
0
Query!
Other mental health disorders
Query!
Mental Health
0
0
0
0
Query!
Depression
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - olanzapine
Treatment: Drugs - carbamazepine
Treatment: Drugs: olanzapine
Treatment: Drugs: carbamazepine
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
To assess the superiority of olanzapine plus carbamazepine versus placebo plus carbamazepine in improving overall manic symptomatology in patients with mania associated with bipolar I disorder.
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Query!
Primary outcome [2]
0
0
Improvement is measured by a reduction in the total score of the Young Mania Rating Scale (YMRS) from baseline to endpoint during the 6-week, double-blind treatment phase.
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Query!
Secondary outcome [1]
0
0
To compare the efficacy and safety of up to 6 weeks of double-blind, concomitant use of olanzapine plus carbamazepine to the concomitant use of placebo plus carbamazepine
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Query!
Secondary outcome [2]
0
0
Using the following assessments:
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Query!
Secondary outcome [3]
0
0
rate of response and time to response over 6 weeks of the double-blind treatment phase, with response defined as a reduction of 50% or more in the YMRS total score from baseline to endpoint.
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Query!
Secondary outcome [4]
0
0
rate of remission and time to remission of mania over 6 weeks of the double-blind treatment phase, with remission defined as a score less than or equal to 12 on the YMRS total score at endpoint
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Query!
Secondary outcome [5]
0
0
reductions from baseline to the endpoint of the 6-week, double-blind treatment phase on the Montgomery-Asberg Depression Rating Scale (MADRS) total score
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Query!
Secondary outcome [6]
0
0
reductions from baseline to the endpoint of the 6-week, double-blind treatment phase on the Clinical Global Impressions-Bipolar Version Severity of Illness Scale (CGI-BP)score
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Query!
Secondary outcome [7]
0
0
rate of switch to depression and time to switch to depression, with switch to depression defined as a baseline MADRS total score less than or equal to 12 followed by
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
Query!
Secondary outcome [8]
0
0
either a post baseline MADRS total score greater than or equal to 16 over the 6 weeks of the double-blind treatment phase OR, hospitalization due to deterioration in clinical
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
Query!
Secondary outcome [9]
0
0
symptoms of depression
Query!
Assessment method [9]
0
0
Query!
Timepoint [9]
0
0
Query!
Secondary outcome [10]
0
0
longitudinal effects from baseline across visits of the double-blind treatment phase by comparing changes in YMRS total scores
Query!
Assessment method [10]
0
0
Query!
Timepoint [10]
0
0
Query!
Secondary outcome [11]
0
0
changes in vital signs and weight, laboratory analytes, and electrocardiograms (ECGs), and the incidence and severity of TEAEs and extrapyramidal symptoms (EPS)
Query!
Assessment method [11]
0
0
Query!
Timepoint [11]
0
0
Query!
Secondary outcome [12]
0
0
using the Barnes Akathisia Scale, Simpson-Angus Scale and the AIMS.
Query!
Assessment method [12]
0
0
Query!
Timepoint [12]
0
0
Query!
Secondary outcome [13]
0
0
the effect of carbamazepine on the plasma concentration of olanzapine via comparison to historic oral steady-state olanzapine concentrations
Query!
Assessment method [13]
0
0
Query!
Timepoint [13]
0
0
Query!
Secondary outcome [14]
0
0
the effect of olanzapine on the plasma concentrations of carbamazepine via a descriptive comparison of the two treatment groups
Query!
Assessment method [14]
0
0
Query!
Timepoint [14]
0
0
Query!
Secondary outcome [15]
0
0
Additional secondary objectives are to assess the maintenance of treatment effect and safety of up to 20 weeks of open-label olanzapine-plus-carbamazepine treatment
Query!
Assessment method [15]
0
0
Query!
Timepoint [15]
0
0
Query!
Secondary outcome [16]
0
0
using the following measures:
Query!
Assessment method [16]
0
0
Query!
Timepoint [16]
0
0
Query!
Secondary outcome [17]
0
0
YMRS total score change from the baseline (Visit 7) to the endpoint of the open-label treatment phase.
Query!
Assessment method [17]
0
0
Query!
Timepoint [17]
0
0
Query!
Secondary outcome [18]
0
0
rate of relapse to mania during the open-label treatment phase. Relapse to mania (patients who relapse to a bipolar I mania or mixed episode) is defined by the following:
Query!
Assessment method [18]
0
0
Query!
Timepoint [18]
0
0
Query!
Secondary outcome [19]
0
0
patient reaches remission of mania (as defined by a YMRS score less than or equal to 12) by the endpoint of the double-blind treatment phase
Query!
Assessment method [19]
0
0
Query!
Timepoint [19]
0
0
Query!
Secondary outcome [20]
0
0
patient obtains a YMRS score greater than or equal to 15 at any time during the open label treatment phase AND/OR becomes hospitalized due to deterioration in clinical symptoms of mania
Query!
Assessment method [20]
0
0
Query!
Timepoint [20]
0
0
Query!
Secondary outcome [21]
0
0
rate of switch to depression during open-label treatment phase, with switch to depression defined as a baseline MADRS total score less than or equal to 12 followed by
Query!
Assessment method [21]
0
0
Query!
Timepoint [21]
0
0
Query!
Secondary outcome [22]
0
0
either a postbaseline MADRS total score greater than or equal to 16 over the 20 weeks of the open-label treatment phase hospitalization due to deterioration in clinical symptoms of depression
Query!
Assessment method [22]
0
0
Query!
Timepoint [22]
0
0
Query!
Secondary outcome [23]
0
0
changes in vital signs and weight, laboratory analytes, and ECGs, and the incidence and severity of TEAEs and EPS using the Barnes Akathisia Scale, Simpson-Angus Scale, and the Abnormal Involuntary Movement Scale (AIMS)
Query!
Assessment method [23]
0
0
Query!
Timepoint [23]
0
0
Query!
Eligibility
Key inclusion criteria
1. Have a diagnosis of bipolar disorder and currently meet DSM-IV-TR criteria for a manic
or mixed episode
2. Female patients must test negative on a serum pregnancy test at the time of enrollment
and agree to use medically accepted contraception throughout the study.
3. Have YMRS score > or = 20 at both the screening (Visit 1) and randomization (Visit 2)
visits.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Have participated (been randomized) in a clinical trial of another investigational
drug (including olanzapine or carbamazepine) within 30 days prior to Visit 1
2. Have a history of agranulocytosis (absolute neutrophil count< 500/uL) during the
patient's lifetime
3. Have acute, serious or unstable medical conditions, including (but not limited to)
inadequately controlled diabetes (HgbA1c>8%); severe hypertriglyceridemia (fasting
triglycerides > or = 500 mg/dl;hepatic insufficiency (specifically any degree of
jaundice); recent cerebrovascular accidents; uncontrolled seizure disorders; serious
acute systemic infection or immunologic disease: unstable cardiovascular disorders
(including ischemic heart disease); or renal, gastroenterologic, respiratory,
endocrinologic, neurologic, or hematologic diseases (specifically current absolute
neutrophil count , <1500/uL)
4. Have a substance dependence (except nicotine or caffeine), based on DSM-IV-TR
criteria, within the 30 days prior to study entry.
5. Require concomitant treatment with any other medication with primarily central nervous
system (CNS) activity, other than those allowed in the protocol.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/09/2004
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
QLD,VIC
Query!
Recruitment hospital [1]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician - Everton Park
Query!
Recruitment hospital [2]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician - Epping
Query!
Recruitment hospital [3]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician - Frankston
Query!
Recruitment hospital [4]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician - Malvern
Query!
Recruitment postcode(s) [1]
0
0
- Everton Park
Query!
Recruitment postcode(s) [2]
0
0
- Epping
Query!
Recruitment postcode(s) [3]
0
0
- Frankston
Query!
Recruitment postcode(s) [4]
0
0
- Malvern
Query!
Recruitment outside Australia
Country [1]
0
0
Greece
Query!
State/province [1]
0
0
Corfu
Query!
Country [2]
0
0
Greece
Query!
State/province [2]
0
0
Kavala
Query!
Country [3]
0
0
Greece
Query!
State/province [3]
0
0
Tripoli
Query!
Country [4]
0
0
Hungary
Query!
State/province [4]
0
0
Budapest
Query!
Country [5]
0
0
Hungary
Query!
State/province [5]
0
0
Debrecen
Query!
Country [6]
0
0
Hungary
Query!
State/province [6]
0
0
Gyula
Query!
Country [7]
0
0
Hungary
Query!
State/province [7]
0
0
Szekesfehervar
Query!
Country [8]
0
0
Russian Federation
Query!
State/province [8]
0
0
Moscow
Query!
Country [9]
0
0
Russian Federation
Query!
State/province [9]
0
0
St. Petersburg
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Eli Lilly and Company
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This trial will assess any efficacious benefit and any safety issues associated with the
concomitant use of olanzapine and carbamazepine for the treatment of patients with bipolar I
disorder, manic or mixed episodes
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00190892
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
Query!
Address
0
0
Eli Lilly and Company
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00190892
Download to PDF